Zhou et al. showed that the advantage of LAG3 blockade compared to PD-L1 blockade was more pronounced in tumor antigen-specific stimulation and concluded that LAG3 can be a promising target for immunotherapy against colorectal cancer52. This evidence concerns the gene CD274 and neoplasm.